• Lineage Cell Therapeutics swung to third-quarter 2026 net income attributable to shareholders of $4.23 million, driven primarily by noncash warrant-liability remeasurement.
• Revenue fell 61% year over year to $1.43 million, primarily due to lower collaboration revenue recognized under the Roche agreement.
• Operating expenses climbed 17% year over year to $8.75 million.
• The acquisition of NeuroAirmid Therapeutics added HUNT1, a clinical-stage Huntington's disease cell therapy, to the pipeline.
• Cash, cash equivalents and marketable securities totaled $45.2 million at September 30, 2026, with planned operations funded into Q2 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261112614737) on November 12, 2026, and is solely responsible for the information contained therein.